AstraZeneca, Ironwood agree US licensing deal for gout treatment
AstraZeneca said it had entered a licensing agreement with Ironwood Pharmaceuticals over exclusive US rights to Zurampic, which is used to treat hyperuricemia associated with uncontrolled gout.
AstraZeneca
11,654.00p
17:15 27/09/24
FTSE 100
8,320.76
16:59 27/09/24
FTSE 350
4,599.36
17:10 27/09/24
FTSE All-Share
4,555.44
17:04 27/09/24
Pharmaceuticals & Biotechnology
22,314.18
17:10 27/09/24
Ironwood will get rights to Zurampic and exclusive US rights to the fixed-dose combination of lesinurad and allopurinol.
AstraZeneca said it planned to submit the fixed-dose combination programme for regulatory review in the second half of 2016.
Ironwood will pay AstraZeneca sales-related and other milestone payments of up to $265m and tiered single-digit royalties on product sales.
AstraZeneca will make and supply Zurampic, provide certain support and services to Ironwood and undertake the FDA post-approval commitment on its behalf.
The agreement does not impact AstraZeneca's financial guidance for 2016.